MG
VRDN icon

Michael Gelband’s Viridian Therapeutics VRDN Stock Holding History

Michael Gelband’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-330,390
Closed -$6.46M – 2116
2026
Q1 		$6.46M Buy
330,390
+237,693
+256% +$7.06M 0.05% 357
2025
Q4 		$2.88M Buy
92,697
+78,284
+543% +$2.15M 0.02% 651
2025
Q3 		$311K Buy
+14,413
New +$260K ﹤0.01% 1297
2025
Q1 		– Sell
-25,724
Closed -$493K – 2038
2024
Q4 		$493K Buy
+25,724
New +$559K ﹤0.01% 1156
2024
Q1 		– Sell
-58,903
Closed -$1.28M – 1997
2023
Q4 		$1.28M Sell
58,903
-115,718
-66% -$1.83M 0.01% 726
2023
Q3 		$2.68M Sell
174,621
-32,590
-16% -$622K 0.03% 583
2023
Q2 		$4.93M Buy
207,211
+80,310
+63% +$2.06M 0.04% 453
2023
Q1 		$3.23M Sell
126,901
-63,753
-33% -$2.04M 0.03% 689
2022
Q4 		$5.57M Buy
190,654
+81,686
+75% +$1.88M 0.08% 323
2022
Q3 		$2.23M Buy
+108,968
New +$1.96M 0.03% 755
2022
Q2 		– Sell
-97,745
Closed -$1.81M – 2496
2022
Q1 		$1.81M Buy
97,745
+20,988
+27% +$403K 0.02% 835
2021
Q4 		$1.52M Buy
+76,757
New +$1.43M 0.02% 874

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Michael Gelband's VRDN Position: Q2 2026 in Review

Michael Gelband sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 330,390 shares — an estimated $6.46M sold.

Michael Gelband first reported a position in VRDN in Q4 2021 and held it in 12 quarters. The position peaked at $6.46M in Q1 2026. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Michael Gelband reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 330,390 Viridian Therapeutics shares in Q2 2026, an estimated $6.46M.
  • Michael Gelband first reported a position in Viridian Therapeutics in Q4 2021 and held it in 12 quarters.
  • Michael Gelband's Viridian Therapeutics position peaked at $6.46M in Q1 2026.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.